Stephane Boissel CEO, TxCell Diego Ardigo Head R&D Rare Diseases Unit Head, Chiesi Farmaceutici SpA Stefano Baila Director of Operations & Business Development, Amenocyte Jacqueline Barry Chief Clinical Officer, Cell and Gene Therapy Catapult Christopher Bravery Director, Advanced Biologicals Ltd Massimilano Cesarini Global Sales Manager, Comecer Doug Danison Vice President and Head of Access, Value, and Evidence Strategy (AVES), bluebird bio Anthony Davies President, Dark Horse Consulting Pam Dhadda Regulatory Affairs Consultant, Cell & Gene Therapy, ERA Consulting Lindy Durrant CSO; Academic Clinical Oncology, Scancell; University of Nottingham Andreas Eberle Vice President & Head of Manufacturing, Co.Don AG Simon Ellison Cell & Gene Therapy Service Director, World Courier Farzin Farzaneh Head of Molecular Medicine, Kings College London Miguel Forte Chief Executive Officer, Zelluna Immunotherapy Michela Gabaldo Head, Alliance Management & Regulatory Affairs, San Raffaele-Telethon Institute for Gene Therapy Miguel Garcia Toscano Head of R&D, Amarna Therapeutics Janet Glassford Senior Quality Assessor, Medicines and Healthcare Products Regulatory Agency (MHRA) Uta Griesenbach Professor, Molecular Medicine, National Heart and Lung Institute, Imperial College London Derek Hei Senior VP, Manufacturing, Quality & Regulatory, BlueRock Therapeutics Shay Hershcovich Co-Founder, Betalin Therapeutics LTD Drew Hope Director, Quality Operations, Autolus Sven Kili VP, Head of Cell & Gene Therapy Development, GlaxoSmithKline Dmitry Kuzmin Managing Partner, 4BIO Capital Romaldas Maciulaitis Clinical & Regulatory Expert, EMA, CAT & CHMP Member, Lithuanian State Medicines Control Agency Christopher Mann Regulatory Affairs Officer, Asphalion John McMannis Executive Vice President, Manufacturing, Mesoblast Margarida Menezes Ferreira Member of the Committee for Advanced Therapies and of the Biologics Working Party, European Medicines Agency (EMA) Anna Mondino Head of Research Unit, Hospital San Raffaele David Morrow Programme Manager Translational Medicine & Drug Development, EATRIS Tim Moser Industry Partnering Specialist, EATRIS Peter Olagunju Vice President Pateitn Operations & Lentiglobin Program , bluebird bio Detlev Parow Head of the Department of Medicines, Therapeutic Appliances and Remedies, DAK-Gesundheit Sarah Pitluck Head, Global Pricing & Reimbursement, Spark Therapeutics Qasim Rafiq Senior Lecturer in Bioprocessing of Regenerative, Cellular & Gene Therapy, University College London Katy Rezvani MD, PhD, Professor of Medicine, Chief, Section of Cellular Therapy, Medical Director GMP Facility, Department of Stem Cell Transplant and Cellular Therapy; CEO, MD Anderson Cancer Center Stephane Boissel; TxCell 1 2
Phacilitate have grown side by side with you –through the bad & the good - since 2005 and we care about what happens next, just as much as you do. Evolution!
Our sponsors make this event special and want to say thanks for their continued support. Sponsors confirmed
View our expert speaker line up we have confirmed so far. More to follow soon so keep coming back to check who is coming to speak this year! Speaker list
Bringing Cell and Gene Therapy Europe to London this year and merging with Immuno-Oncology Frontiers to create Phacilitate Leaders Europe. Cell & Gene Therapy Europe
Immuno-Oncology Frontiers is merging with Cell and Gene Therapy Europe this year as we evolve and grow with the industry. Immuno-Oncology Frontiers
Advanced therapies are reaching a maturation point but without sustainable, global investment we’ll stop seeing revolutions in the future of healthcare. Investment for Advanced Therapies
